August 15, 2018 - OHSU Research News
Three drug discovery projects have been named recipients of the 2018 Biomedical Innovation Program awards. The awards provide funds, project management, and mentorship to facilitate the development of innovative technologies at OHSU and accelerate their translation to the marketplace. To see the full list of winners and their abstracts, click here.
Murdock Trust announces record year of giving
July 5, 2018 - East Oregonian
The M.J. Murdock Charitable Trust releases its 2017 annual report on grant awards; the OHSU Foundation received $475K for a magnetic resonance scanner and $59K for OmnEcoil, a prostatic MR imaging and biopsy device. To see the full article, click here.
July 4, 2018 - NBC Nightly News
The Levo System retrains the brain to ignore noise by recreating each patient's unique ringing sounds. A recent study reported improvement after three months. To see the full video, click here.
How a $600M jolt could get OHSU's promising AIDS vaccine to market
June 14, 2018 - Portland Business Journal
Tomegavax, which was formed to commercialize Dr. Louis Picker's novel HIV vaccine, struggled to gain traction with investors. Then Vir Biotechnology came along. To see the full article, click here.
Feb. 28, 2018 - Portland Business Journal
Sept. 22, 2017 - OHSU Research News
More than 250 scientists and entrepreneurs gathered last week at the OHSU Commercialization Conference, now in its fifth year. The takeaways? Disruptive innovation in science follows years of research that is carefully framed to address specific problems; business engagement can help move scientific discoveries to the patient; and OHSU’s structure that locates research outside the five schools creates special opportunities for transdisciplinary research, training, and education. To see the full article, click here.
Progressive MS is more severe, yet there are fewer therapies. To see the full article, click here.
Sept. 14, 2017 - Portland Business Journal
The focus should be on solving a problem and patient outcomes, not innovation for its own sake, he told attendees of a conference today. To see the full article, click here.
Sept. 7, 2017 - Portland Business Journal
Millions in grants, a key strategic alliance and a novel solution for a life-threatening problem have propelled Aronora drugs closer to the commercial market. To see the full article, click here.
Aug. 2, 2017 - Portland Business Journal
News blasted around the world today that OHSU scientists successfully corrected mutated genes in human embryos for the first time. The breakthrough, published in the journal Nature, could have major implications for halting inherited diseases before they are passed down through the generations. But the method is also controversial, raising alarms about the potential for "designer babies." To see the full article, click here.
June 8, 2017 - Innovosource
Oregon Health & Science University’s Oregon Clinical & Translational Research Institute Biomedical Innovation Program (BIP) takes an integrated approach to identifying, supporting, and accelerating the commercialization of new healthcare technologies. The BIP facilitates commercialization through direct project management, inventor education, and external feedback/advisory support. In addition they offer a suite of funding options to nurture promising translational research and proof of concept through the capital ‘valley of death”. To see the full article, click here.
OHSU's latest tech spinout? A dome-shaped data center
May 31, 2017 - Portland Business Journal
Oregon Health and Science University is known for spawning healthcare and biotech startups, but one of its latest spinouts is in a seemingly surprising field: data center design. A pair of Portland entrepreneurs have licensed technology from OHSU developed by Perry Gliessman, its former director of technology who created a new kind of data center that significantly decreases the amount of energy it consumes. Their startup, called Server Dome, hopes to sell more data centers based off the successful design of OHSU's "Data Dome," a geodesic dome-shaped data center hat has been operating for three years at the university's West Campus in Hillsboro. To see the full article, click here.
Researchers moving blood testing from the clinic to the home
April 11, 2017 - OHSU Research News
The device, called TouchSpot, uses dried blood spot sampling, a technique in which a small amount of blood from the finger or heel is drawn and then dried before analysis. In order to serve as an alternative to venipuncture, a precise amount of blood must be delivered to filter paper. Collecting a precise quantity of blood and preventing damage to the filter paper are primary challenges to developing a dried blood spot sampling device that can stand in for intravenously collected samples. To see the full article, click here.
OCTRI Biomedical Innovation Program, funding for drug discovery
Mar. 3, 2017 - OHSU Research News
The Oregon Clinical and Translational Research Institute (OCTRI) and the Office of Technology Transfer & Business Development (TTBD) are pleased to announce a funding opportunity to support drug discovery and therapeutic technology development efforts at OHSU.The Biomedical Innovation Program (BIP) Drug Discovery/Therapeutic Track is a funding mechanism that aims to accelerate creative, trans-disciplinary drug discovery, and therapeutic development research. Examples of responsive projects may include (but are not limited to) research involving target validation, development of small molecules, antibodies, vaccines and biologics. To see the full article, click here.
OHSU's HIV vaccine technology acquired by Bay Area biotech
Jan. 25, 2017 - The Oregonian
A San Francisco-based biotech company has acquired vaccine research by Oregon Health & Science University scientists, marking a critical step toward commercialization of a promising HIV vaccine. The deal involves the startup Vir Biotechnology Inc. buying TomegaVax Inc., an OHSU spinoff that holds the rights to the vaccine technology developed by Dr. Louis Picker and Klaus Frueh at OHSU's Vaccine and Gene Therapy Institute in Beaverton. To see the full article, click here.
Portland vaccine developer acquired by 'immune programming' startup
Jan. 6, 2017 - Portland Business Journal
A San Francisco-based biotechnology company that publicly launched today has acquired Portland-based TomegaVax Inc., an Oregon Health & Science University spinoff that is pursuing an HIV vaccine. Vir Biotechnology is taking on "some of the world's most challenging infectious diseases for which solutions are non-existent or inadequate," the company's announcement says. The company is "seeking to apply immune programming on an unprecedented scale." To see the full article, click here.
David Huang, M.D., Ph.D., receives National Academy of Inventors Award
Dec. 13, 2016 - OHSU Research News
OHSU Casey Eye Institute researcher David Huang, M.D., Ph.D., has been named a Fellow of the National Academy of Inventors. Academic inventors and innovators elected to the rank of NAI Fellow were nominated by their peers for outstanding contributions to innovation in areas such as patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation. To see the full article, click here.
2016 BIP Drug Discovery awardees announced
Jul. 7, 2016 - OHSU Research News
The Oregon Clinical & Translational Research Institute and OHSU Technology Transfer and Business Development are pleased to announce the funding of two Biomedical Innovation Program drug discovery awards. A new track supports drug discovery platforms and early stage therapeutic technology projects, including validation of drug targets and the development of small molecules, antibodies, vaccines, or biologics. The BIP provides funds, project management, and mentorship to facilitate the development of innovative technologies at OHSU, and accelerate their translation from academia to the marketplace. To see the full article, click here.
How OHSU's Research Spins Off into Tech Start-Ups
Jun. 24, 2016 - PDX Monthly
Dan Dorsa is OHSU senior vice president of research. He explains the MedTech Alliance, which spins off the university's research into private tech companies. To see the full article, click here.
OHSU's HIV researcher wins more than $14 million
Jun. 20, 2016 - The Oregonian
Federal officials have given $42 million to top HIV researchers, including Dr. Louis Picker of Oregon Health & Science University. Picker has developed one of the most promising HIV vaccines in the country. He'll get a little over a third of the grant from the National Institutes of Health. The same amount will go to Dr. Dan Barouch of Harvard Medical School. Barouch has a promising vaccine that uses a different approach. Six other scientists will share the rest of the money by performing analyses for the two researchers. To see the full article, click here.
Is Portland another Silicon Valley… for Life Sciences?
May 9, 2016 - The Pulse by GE Healthcare
Start-ups are no longer exclusively for mobile app and social network creators. With advancements in personalized medicine and cell biology, the next big thing may come from a burgeoning Life Sciences entrepreneur. Vitruvian Networks, Inc., for example, a newly announced brainchild of GE Ventures and Mayo Clinic Ventures, may help make it possible for mass manufactured cell and gene therapies to reach thousands of patients at their bedsides. But like any other startups, these Life Sciences endeavors need investment to come to life. That's where Portland comes in. The Department of Technology Transfer and Business Development at Oregon Health & Science University hosts an annual Startup Symposium, the most recent of which occurred this past March, where budding life sciences entrepreneurs get the chance to meet investors and researchers who could bring their visions to life. To see the full article, click here.
GE Healthcare and OHSU refine their collaboration
Apr. 1, 2016 - Portland Business Journal
GE Healthcare has long entered into partnerships with universities around the globe.And Oregon Health & Science University is high on that list. GE and OHSU signed a Memorandum of Understanding to collaborate on a variety of health care projects, which the two are in the process of narrowing down as they finalize a "large master agreement" by July. To see the full article, click here.
OHSU, Intel sign up 2 major cancer centers for ambitious cloud project
Mar. 31, 2016 - Portland Business Journal
Oregon Health & Science University and Intel Corp. have expanded the participants in their Collaborative Cancer Cloud to include two other leading cancer research institutions. Dana-Farber Cancer Institute in Boston and Ontario Institute for Cancer Research in Toronto are on board with the ambitious project to share genomic, imaging and clinical data with a goal of better understanding the root causes of cancer in order to better tailor treatments to each individual. To see the full article, click here.
Healthtech: Portland startup takes video platform to market
Feb. 23, 2016 - Portland Business Journal
ReelDx, a Portland health IT startup, today announced that its platform has gone from the beta phase into commercial availability. Medvid.io, a HIPAA-compliant, cloud-based video management platform, was released last year at the HIMSS conference in Chicago as a closed beta program. To see the full article, click here.
A look at three Oregon health care profs-turned-entrepreneurs
Jan. 15, 2016 - Portland Business Journal
Two Oregon Health & Science University professors are highlighted in the Portland Business Journal's special report on professors turned entrepreneurs. To see the full article, click here.
OHSU Spinoff raises $11M to tackle rare brain disease
Jan. 12, 2016 - Portland Business Journal
An Oregon Health & Science University startup has raised $11.45 million to continue developing therapeutics for neurological disorders, according to a filing with the U.S. Securities and Exchange Commission. NeuroVia Inc., which has offices in Portland and Cambridge, Massachusetts, is working on an agent to treat a rare genetic disease. Known as X-ALD for short, it primarily affects adolescent boys and young men and produces a spectrum of debilitating neurological symptoms. To see the full article, click here.
OCTRI announces 2016 Biomedical Innovation Program award recipients
Jan. 6, 2016 - OHSU Research News
The Oregon Clinical & Translational Research Institute (OCTRI) is pleased to announce the funding of three research awards through its Biomedical Innovation Program. The BIP aims to cultivate, select and provide strong program management for promising translational projects that develop new biomedical devices, diagnostics, and software. The primary objective of the BIP is to facilitate development of innovative technologies from academia to the marketplace, and thus to make a meaningful impact on human health. To see the full article, click here.
After Intel, OHSU teams with another tech giant to tackle complex research
Nov. 13, 2015 - Portland Business Journal
Oregon Health & Science University and GE Healthcare plan to collaborate on cardiovascular research, imaging and Big Data. OHSU and GE Healthcare announced that beginning next month, they will launch "several pilot programs that will pave the way for deeper research collaborations, joint grant applications and the exploration of new areas for future research collaborations." To see the full article, click here.
OHSU Knight Cardiovascular creates company to build first Total Artificial Heart
Nov. 5, 2015 - Portland Business Journal
About 3,000 Americans sit on the waiting list for a heart transplant on a given day, but only about 2,000 donor hearts are available each year, according to the National Institutes of Health. A Portland-based startup could eventually help fill that need. OregonHeart Inc. is in the very early stages of developing the world's first Total Artificial Heart. Oregon Health &Science University founded the company and invested $5 million. To see the full article, click here.
Apple Announces New ResearchKit Studies for Autism, Epilepsy & Melanoma
Oct. 15, 2015 - Apple, Inc.
ResearchKit turns iPhone® into a powerful tool for medical research by helping doctors, scientists and other researchers gather data more frequently and more accurately from participants using iPhone apps. With ResearchKit, study participants can review an interactive informed consent process, easily complete active tasks or submit survey responses, and choose how their health data is shared with researchers, making contributions to medical research easier than ever. To see the full article, click here.
New Apple ResearchKit trials focus on epilepsy, autism and skin cancer
Oct. 15, 2015 - Fortune Magazine
Apple launched ResearchKit, its iOS-based platform for clinical research, in March with an initial class of five trials focused on a range of health conditions. Nearly seven months later, the tech giant is welcoming three new trials focused on epilepsy, autism, and melanoma. To see the full article, click here.
Portland startup commercializes OHSU colonoscopy technology
Oct. 9, 2015 - Portland Business Journal
Due North, a portland startup that specializes in taking ideas from the lab to market, exclusively licensed an OHSU technology called CORI 2 (Clinical Outcomes Reporting Informatics) that includes tracking and reporting software and generate photographs that get incorporated into reports. To see the full article, click here.
Portland wellness company nets $1.4M NIH grant to help firefighters
Aug. 12, 2015 - Portland Business Journal
Provata Health, formerly called Odyssey Science Innovations, received the funding through the National Institutes of Health's Small Business Technology Transfer Phase II funding program.Provata’s wellness program, called Healthy Team Healthy U, was developed at Oregon Health & Science University. It was tested on a variety of populations, including Portland Fire & Rescue, over a 25-year period. To see the full article, click here.
Can the brave new world of neurotechnology help an OHSU surgeon find a cure for obesity?
Jul. 13, 2015 - Oregon Business
In 1990 Oregon Health & Science University neuro-surgeon Kim Burchiel performed the very first Deep Brain Stimulation surgery in North America, as part of a Food and Drug Administration-approved clinical trial for patients suffering from the debilitating symptoms of Parkinson’s disease. To see the full article, click here.
Knight Challenge Nets Oregon Health & Science University $1B for Cancer Research
Jun. 25, 2015 - ABC News
Oregon Health & Science University has raised $1 billion for cancer research. The announcement fulfills the ambitious fundraising goal known as the Knight Cancer Challenge. In 2013, Knight and his wife, Penny, pledged to give OHSU $500 million provided that the organization could raise a matching $500 million in two years’ time. To see the full article, click here.
OHSU grantees hope to regenerate nerves, create better dental composites and treat breast cancer
Jun. 5, 2015 - Portland Business Journal
Oregon Health & Science University’s BioScience Innovation Program awarded three technology development grants to scientists with promising early-stage research projects.The program leverages funds through the University Venture Development Fund, a state tax-credit program established in 2003 to further commercialization of university research. The funds support promising technologies and helps move them to the “proof of concept” stage, so they can attract outside investment or venture capital. To see the full article, click here.
First-of-its-kind West Nile virus vaccine now in Phase I clinical trials
May 7, 2015 - OHSU News
A novel investigational West Nile virus vaccine discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University is being evaluated in an NIH-sponsored Phase 1, first-in-human, clinical trial at Duke University. Although several early-stage West Nile virus vaccine clinical trials have been completed to date, no human vaccine has been approved for commercial use. In regards to this research project, the HydroVax™ technology is being commercialized by Najit Technologies, Inc., an OHSU startup company. To see the full article, click here.
OHSU researchers look to patent breakthrough eye test technology
Apr. 21, 2015 - Portland Business Journal
Researchers at Oregon Health & Science University’s Casey Eye Institute say technology they've developed has huge advantages over conventional techniques for diagnosing and managing the leading causes of blindness in the U.S.Optical coherence tomography (OCT) angiography can improve the clinical management of macular degeneration, diabetic eye disease and glaucoma. It could mostly replace current dye-based angiography in managing these diseases, according to research published Monday in the Proceedings of the National Academy of Sciences. To see the full article, click here.
Study shows new technology may improve management of leading causes of blindness
Apr. 20, 2015 - OHSU News
Research published today in the Proceedings of the National Academy of Sciences (PNAS) demonstrates that technology invented by researchers at Oregon Health & Science University’s Casey Eye Institute can improve the clinical management of the leading causes of blindness. Optical coherence tomography (OCT) angiography could largely replace current dye-based angiography in the management of these diseases. To see the full article, click here.
Cover Story: OHSU taps Intel to tackle cancer
Apr. 17, 2015 - Portland Business Journal
Two years ago, Oregon Health & Science University and Intel Corp. announced an ambitious project: crack the codes of cancer and other complex diseases. “We started with an appreciation of the fact we’re in a remarkable time in medicine,” said Joe Gray, a physicist and associate director for translational research at OHSU’s Knight Cancer Institute... To see the full article, click here. (Note: PBJ subscription needed)
Healthtech: Portland Startup will tape your doctor visit so you can watch it later
Apr. 14, 2015 - Portland Business Journal
Portland-based ReelDx announced today that its secure telemedicine video platform is now available to software developers.CEO and co-founder Bill Kelly said ReelDx’s medvid.io platform enables any software developer to add cloud-based Hipaa-compliant video management. To see the full article, click here.
Report Shows Academia-Industry Technology Transfer Contributed Up to $1.18 Trillion to U.S. Economy Since 1996
Mar. 18, 2015 - Biotechnology Industry Organization
A newly released independent study, commissioned by the Biotechnology Industry Organization (BIO), documents the significant impact academia-industry technology transfer makes to the U.S. economy. The report, entitled, “The Economic Contribution of University/Nonprofit Inventions in the United States: 1996- 2013,” estimates that, during this 18-year time period, academia-industry patent licensing bolstered U.S. gross industry output by up to $1.18 trillion, U.S gross domestic product (GDP) by up to $518 billion, and supported up to 3,824,000 U.S. jobs. To see the full article, click here.
Healthtech: Portland biotech startup forms partnership with pharmaceutical heavyweight
Mar. 6, 2015 - Portland Business Journal
Aronona is partnering with Bayer HealthCare's Global Biologics Development group in Berkeley, California, for pre-clinical manufacturing. The alliance gives Aronora access to Bayer HeatlhCare's manufacturing expertise across the entire drug development process. To see the full article, click here.
The Pitch: A test to keep the heart pumping
Feb. 13, 2015 - Portland Business Journal
The Affordable Care Act places an emphasis on preventive medicine, and one of the top conditions that doctors — and patients — would like to prevent is cardiovascular disease. That's where Portland startup Gamma Therapeutics comes in. An outgrowth of the research by David Farrell at Oregon Health & Science University, Gamma Therapeutics' flagship product tests for risk of cardiovascular disease, heart attack and stroke. To see the full article, click here.
FEI, OHSU expand their partnership for high-powered microscopes
Dec. 15, 2014 - Portland Business Journal
A new FEI instrument, the FEI CorrSight, has been added to the OHSU-FEI electron microscopy suite at OHSU's Living Lab for Cell Biology. CorrSight is an advanced light microscope that enables researchers to observe live cell dynamics using visible light microscopy. To see the full article, click here.
The Pitch: A treatment for severe stroke patients
Dec. 12, 2014 - Portland Business Journal
T he conventional therapy for stroke victims basically involves repeating the same movements they have difficulty doing. That may work for less impaired people, but it doesn't do a thing for the patients who are the worst off. Paul Cordo, a professor of biomedical engineering at Oregon Health & Science University, has come up with a solution to help the 3 million Americans who fall into the severely impaired category. To see the full article, click here.
‘Just pee in a cup’ and other big ideas from OHSU inventors
OHSU conferences aim to bring together inventors, investors and industry
Oct. 28, 2014 - Portland Business Journal
In an effort to bring together inventors and health-related startups, OHSU's office of Technology Transfer & Business Development (TTBD) is holding two separate, but back-to-back events this October. To see the full article featured in the Portland Business Journal, click here.
Cover Story: A weight loss pill that could fatten OHSU's wallet
Oct. 3, 2014 - Portland Business Journal
In 2003, OHSU's office of Technology Transfer & Business Development (TTBD) created a startup company called Orexigen Therapeutics, Inc. Since its formation, Orexigen Therapeutics has hit two major milestones. In 2007, venture capitalists took notice of the company, and took the company public, and raised $255 million. Then in recent months, Orexigen's weight loss drug Contrave, received FDA approval. To see the full cover story featured in the Portland Business Journal, click here.
OHSU breaks another record for tech spinoffs
Sept. 19, 2013 - Portland Business Journal
Technology transfers at Oregon Health & Science University smashed records this year, with more patents applied for and issued, and more license agreements signed. “It’s a win-win situation all around,” said Andrew Watson, director of technology transfer in OHSU’s Technology Transfer & Business Development department. “We’re able to move technology outside the walls of OHSU to a company that’s able to develop it. ”... To see the full article, click here.
Neuro Kinetics in Tech Transfer Licensing Deal with Oregon Health & Science University
May 16, 2013 - MarketWatch by Wall Street Journal
Medical device manufacturer Neuro Kinetics, Inc. stated that it has licensed rights to patented diagnostic software developed at Oregon Health & Science University (OHSU) that enables medical researchers to perform Pulse-Step-Sine Rotation tests to better understand vestibular system abnormalities. To see the full article, click here.
OHSU Hits Tech Transfer Record
Nov. 23, 2012 - Portland Business Journal
Oregon is on the cusp of a golden age in university-driven commercial research and licensing. Oregon Health & Science University revealed this week it has reached all-time highs in terms of patents, research agreements and research funds collected from private companies. To see the full article, click here.
Universities Hitting Tech Transfer Strides
Nov. 21, 2012 - Portland Business Journal
Oregon universities are reaping the benefits from their tech transfer offices. To see the full article, click here.
OHSU to Double Tech Transfer Office
Jul. 15, 2011 - Portland Business Journal
Oregon Health & Science University will roughly double the number of staffers in its technology transfer office, from 14 to 27. OHSU’s associate vice president for technology transfer and business development, projected that the heartier staff could increase overall commercialization activity by 50 percent by mid-2013. To see the full article, click here.
MolecularMD adds Two New Clients to Bolster Role as OHSU Tech Transfer Success Story
May 29, 2007 - GenomeWeb
MolecularMD, based in Portland, Ore., is one of the most recent spinout biotechnology companies from Portland’s Oregon Health and Science University. Founded last June, MolecularMD is developing a battery of assays to help match specific patients with tailored cancer therapies and to monitor the progress of their disease. The company’s initial focus is on molecular testing of chronic myeloid leukemia, but the firm is evolving into other disease areas such as acute myelogenous leukemia, glioma, and lung cancer. To see the full article, click here.